SOURCE: The Bedford Report

The Bedford Report

November 04, 2011 08:16 ET

Highly Anticipated Drugs From BioSante and AEterna Zentaris May Not Be as Lucrative as Expected

The Bedford Report Provides Equity Research on BioSante & AEterna Zentaris

NEW YORK, NY--(Marketwire - Nov 4, 2011) - Shares throughout the biotechnology sector have been exceptionally volatile of late as developments regarding government approvals, litigation and shockingly disappointing earnings elicit large movements in stock prices. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ). Access to the full company reports can be found at:

This earnings season has been cruel to the biotech industry. Dendreon's announcement that sales of its revolutionary prostate cancer drug, Provenge, have come in significantly below expectations for the year has caused a downward push for the entire sector, as investors abandon shares of firms nearing the launch of other highly anticipated drugs.

On the upside for the industry, analysis by the professional services firm BDO argues that larger Pharmaceutical firms are increasing reliance on biotech companies to fill its pipeline, which has been a net positive for small biotech companies.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. The company's lead products include LibiGel for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder. Last month the company announced that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information